Humana Inc. $HUM Holdings Lifted by Aberdeen Group plc

Aberdeen Group plc raised its holdings in Humana Inc. (NYSE:HUM) by 39.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 240,336 shares of the insurance provider’s stock after acquiring an additional 68,175 shares during the quarter. Aberdeen Group plc owned 0.20% of Humana worth $62,475,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in HUM. Elevation Point Wealth Partners LLC acquired a new position in shares of Humana in the 2nd quarter valued at $32,000. Mather Group LLC. acquired a new position in Humana during the third quarter valued at $34,000. AlphaCore Capital LLC purchased a new stake in shares of Humana in the second quarter worth approximately $39,000. Private Wealth Management Group LLC grew its holdings in shares of Humana by 47.5% during the 3rd quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock valued at $39,000 after acquiring an additional 48 shares in the last quarter. Finally, SJS Investment Consulting Inc. grew its stake in Humana by 19,300.0% in the third quarter. SJS Investment Consulting Inc. now owns 194 shares of the insurance provider’s stock valued at $50,000 after purchasing an additional 193 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

More Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

Humana Trading Up 2.8%

Shares of NYSE HUM opened at $183.92 on Monday. Humana Inc. has a 1-year low of $169.61 and a 1-year high of $315.35. The company has a 50-day moving average of $244.65 and a two-hundred day moving average of $261.02. The company has a market cap of $22.12 billion, a PE ratio of 18.73, a P/E/G ratio of 1.96 and a beta of 0.44. The company has a current ratio of 2.00, a quick ratio of 2.02 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM) last released its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. The company had revenue of $32.64 billion during the quarter, compared to the consensus estimate of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The firm’s quarterly revenue was up 11.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HUM has been the topic of several analyst reports. Sanford C. Bernstein restated an “outperform” rating and set a $344.00 price target on shares of Humana in a research note on Tuesday, January 6th. Leerink Partners lowered their price target on Humana from $267.00 to $185.00 and set a “market perform” rating on the stock in a research report on Thursday. Morgan Stanley set a $146.00 price target on Humana in a research report on Thursday. TD Cowen reduced their price target on shares of Humana from $260.00 to $173.00 and set a “hold” rating for the company in a report on Friday. Finally, Zacks Research lowered Humana from a “hold” rating to a “strong sell” rating in a report on Thursday, January 1st. Seven analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and five have assigned a Sell rating to the company. According to MarketBeat.com, Humana currently has an average rating of “Hold” and a consensus target price of $238.29.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.